Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock ...

Key Takeaways Many skin conditions that cause induration require close follow-up care, particularly if symptoms begin to worsen and/or if treatment (such as antibiotics) is ineffective. Skin ...